Popular
Ready, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion
CME/CEReady, Set, Act! Opportunities to Address Persistent Unmet Needs in Patients With HFrEF: A Case-Based Discussion
Carolyn Lam, MD, PhD
Stephen J. Greene, MD
Hypopigmentation in Atopic Dermatitis Patients with Skin of Color
Dermatology Hub: Neuroimmune NetworkHypopigmentation in Atopic Dermatitis Patients with Skin of Color
Cheri Frey, MD
When Skin and Itch Do Not Match in Atopic Dermatitis
Dermatology Hub: Neuroimmune NetworkWhen Skin and Itch Do Not Match in Atopic Dermatitis
Elizabeth Swanson, MD, FAAD
Ambulatory Monitoring Approaches for PSVT: Which One and When?
MinuteCE®Ambulatory Monitoring Approaches for PSVT: Which One and When?
Jennifer Carlquist, PA-C
Brian P. Rose, PA-C, MPH, AACC
Programs
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
NephrologyINFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Peter Rossing, MD, DMSc
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Diabetes and EndocrinologyReal-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Csaba P. Kovesdy, MD
Hypopigmentation in Atopic Dermatitis Patients with Skin of Color
Dermatology Hub: Neuroimmune NetworkHypopigmentation in Atopic Dermatitis Patients with Skin of Color
Cheri Frey, MD
Ambulatory Monitoring Approaches for PSVT: Which One and When?
MinuteCE®Ambulatory Monitoring Approaches for PSVT: Which One and When?
Jennifer Carlquist, PA-C
Brian P. Rose, PA-C, MPH, AACC
- CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona Disease Deep Dive: The Evolving Role of Nonsteroidal Topical Therapy for Atopic Dermatitis
Practical DermatologyDisease Deep Dive: The Evolving Role of Nonsteroidal Topical Therapy for Atopic Dermatitis
Walter Liszewski, MD
Adelaide Hebert, MD
Clinical Practice
Hypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis
CME/CEHypoparathyroidism – The Critical Role of Genetics in Your Differential Diagnosis
Dolores Shoback, MD
Michael T. Collins, MD
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
CardiologyAPOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Erik Stroes
Recurrence as the Rule: BD Symptoms Persist and Cycle
MinuteCE®Recurrence as the Rule: BD Symptoms Persist and Cycle
Jose M. Rubio, MD, PhD
Sunny X. Tang, MD
Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum
MinuteCE®Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum
Jose M. Rubio, MD, PhD
Sunny X. Tang, MD
Brian P. McDonough, MD, FAAFP
Michael Moor, MD, PhD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Doctors Lounge
The Science of Exceptions: Setting the Safety Bar for Clinical AI
The ConvergenceThe Science of Exceptions: Setting the Safety Bar for Clinical AI
Brian P. McDonough, MD, FAAFP
Suvrankar Datta, MD
Engaging Patients and Caregivers About Digital Therapeutics
Medical Industry FeatureEngaging Patients and Caregivers About Digital Therapeutics
Charles Turck, PharmD, BCPS, BCCCP
Maggie Emerson, DNP, APRN, PMHNP-BC
“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
The Convergence“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
Brian P. McDonough, MD, FAAFP
Rajiv Kumar, MD
Optimizing Medical Affairs Approaches with CME Best Practices
MAPSChatsOptimizing Medical Affairs Approaches with CME Best Practices
Matt Birnholz, MD
Karen Roy, MSc
Bruno Batinica, MD
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
Brian P. McDonough, MD, FAAFP
Raja-Elie E. Abdulnour, MD
CME
Navigating the Limitations of Current BD Therapies
MinuteCE®Navigating the Limitations of Current BD Therapies
Jose M. Rubio, MD, PhD
Sunny X. Tang, MD
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
- MinuteCE®
Exploring the Potential Role of Emerging Muscarinic Therapies in the Treatment of Bipolar Disorder
Jose M. Rubio, MD, PhD
Sunny X. Tang, MD
Oral GLP-1 RA Therapy in Type 2 Diabetes and High Cardiovascular Risk
CME/CEOral GLP-1 RA Therapy in Type 2 Diabetes and High Cardiovascular Risk
Brian P. McDonough, MD, FAAFP
Silvio Inzucchi, MD
Jay H. Shubrook, DO, FACOFP, FAAFP
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Industry Feature
Single-Port Robotics Improves Outcomes for Thoracic Surgery
Medical Industry FeatureSingle-Port Robotics Improves Outcomes for Thoracic Surgery
Benjamin Lee, M.D.
Jeffrey Port, M.D.
Jonathan Villena-Vargas, M.D.
What Is on the ‘HERIZON’ in 1L HER2+ Gastroesophageal Adenocarcinoma?
Medical Industry FeatureWhat Is on the ‘HERIZON’ in 1L HER2+ Gastroesophageal Adenocarcinoma?
Jennifer Caudle, DO, FACOFP
Syma Iqbal, MD
The First Approved All-Oral, Fixed Duration Treatment for CLL: Insights from the AMPLIFY Trial
Project Oncology®The First Approved All-Oral, Fixed Duration Treatment for CLL: Insights from the AMPLIFY Trial
Jennifer Caudle, DO, FACOFP
Nicole Lamanna, MD
Putting Into Practice: ctDNA Monitoring of ESR1 Mutations During 1L HR+/HER2− Advanced Breast Cancer
Innovations In MedicinePutting Into Practice: ctDNA Monitoring of ESR1 Mutations During 1L HR+/HER2− Advanced Breast Cancer
Unraveling PMR Pathophysiology: The Central Role of IL-6
Medical Industry FeatureUnraveling PMR Pathophysiology: The Central Role of IL-6
Charles Turck, PharmD, BCPS, BCCCP
Adam Brown, MD
Megan Sullivan, MD
Earlier ESR1m Detection May Delay Endocrine Resistance in HR+/HER2- Advanced Breast Cancer
Innovations In MedicineEarlier ESR1m Detection May Delay Endocrine Resistance in HR+/HER2- Advanced Breast Cancer